{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-25-000037","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2025-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.340522+00:00","generated_at":"2026-05-18T01:57:58.599107+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"confidence":"high","headline":"Edwards Q2 sales up 11.9% to $1.53B; raises full-year guidance","bullets":["Q2 GAAP EPS $0.57; adjusted EPS $0.67.","TAVR sales $1.1B (+8.9%); TMTT $134.5M (+61.9%); Surgical $267M (+7.7%).","Full-year sales growth guidance raised to 9-10% (from 8-10%); adjusted EPS expected at high end of $2.40-$2.50.","SAPIEN M3 CE Mark approved in Q2; 10-year PARTNER II data affirm durability.","Q3 guidance: sales $1.46-$1.54B, adjusted EPS $0.54-$0.60."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-25-000037","json":"https://secwatch.observer/filing/0001099800-25-000037.json","markdown":"https://secwatch.observer/filing/0001099800-25-000037.md","text":"https://secwatch.observer/filing/0001099800-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980025000037/0001099800-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980025000037/ew-20250724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T01:57:58.599107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}